Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio10.26
Quick Ratio9.54
Price-To-Earnings
Trailing P/E Ratio-46.88
Forward P/E Ratio-30.52
P/E GrowthN/A
Sales & Book Value
Annual Sales$96.30 million
Price / Sales8.30
Cash FlowN/A
Price / CashN/A
Book Value$3.98 per share
Price / Book6.60
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-16,360,000.00
Net Margins-17.22%
Return on Equity-15.01%
Return on Assets-13.27%
Miscellaneous
Employees327
Outstanding Shares30,450,000
Market Cap$837.50 million
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) issued its quarterly earnings data on Wednesday, August, 1st. The medical equipment provider reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. The medical equipment provider earned $26.30 million during the quarter, compared to analysts' expectations of $28.15 million. Intersect ENT had a negative net margin of 17.22% and a negative return on equity of 15.01%. The business's revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.08) EPS. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What price target have analysts set for XENT?
8 equities research analysts have issued 12 month price objectives for Intersect ENT's shares. Their forecasts range from $32.00 to $48.00. On average, they expect Intersect ENT's share price to reach $39.50 in the next year. This suggests a possible upside of 50.5% from the stock's current price. View Analyst Price Targets for Intersect ENT.
What is the consensus analysts' recommendation for Intersect ENT?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. BTIG Research analysts commented, "Following this morning’s early earnings announcement, management discussed the issues underlying the weak report and reduced sales guidance. Most troubling to us was that instead of SINUVA being easily available via the specialty pharmacy channel, many payors are requiring doctors to either use a payor-affiliated specialty pharmacy partner or to use a buy-and-bill approach. This means doctors must pay to acquire SINUVA, then bill for it and hope they are paid back. While XENT mgmt believes this hurdle can be overcome by showing reluctant docs proof of payment and expanding the salesforce, we think it will be more difficult to change the way ENTs operate. We cut our SINUVA sales estimate for 2H and beyond while also dampening modeled growth rates for PROPEL." (8/2/2018)
- 2. Canaccord Genuity analysts commented, "We remain buyers ahead of trial data coming up in 4Q18 We believe the stock’s pullback presents opportunity ahead of a catalyst-rich period that is coming up in the near to medium-term. Specifically, we await results on long- term safety of rimegepant (acute treatment of migraine) and a Phase 3 trial on the orally-dissolving tablet (ODT) formulation of rimegepant. Given the behavior of the molecule in two Phase 3 trials so far (see here) and a validated mechanism (Allergan also reported positive results for its ubrogepant; see here), we expect these results to support a potential filing of rimegepant in 2019. a more detailed list of BHVN-related catalysts. We also continue to believe that rimegepant could be a meaningful player in the market for the acute treatment of migraine, and we are reiterating our BUY on BHVN." (8/1/2018)
- 3. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (5/5/2018)
- 4. Northland Securities analysts commented, "We are raising our FY18 and FY19 numbers, in part due to elevated expectations on SINUVA. In our view, this story of marginal beats and managing Street expectations" is not enough to elevate the stock from its current 10x sales multiple." (5/2/2018)
Are investors shorting Intersect ENT?
Intersect ENT saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 807,217 shares, an increase of 57.0% from the July 13th total of 514,294 shares. Based on an average trading volume of 359,466 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.8% of the company's shares are sold short. View Intersect ENT's Current Options Chain.
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Nevro (NVRO), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Luminex (LMNX), Cryolife (CRY), Atrion (ATRI), AtriCure (ATRC), Tactile Systems Technology (TCMD) and OraSure Technologies (OSUR).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 48)
- Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 60)
- Mr. Richard E. Kaufman, Sr. VP of R&D and Operations & COO (Age 56)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
- Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 54)
Has Intersect ENT been receiving favorable news coverage?
Press coverage about XENT stock has been trending positive this week, Accern Sentiment reports. Accern rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intersect ENT earned a news impact score of 0.25 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 46.56 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Intersect ENT.
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.59%), Jennison Associates LLC (4.35%), FMR LLC (3.51%), Renaissance Technologies LLC (1.51%), OppenheimerFunds Inc. (1.31%) and Cadian Capital Management LP (1.10%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Dana G Jr Mead, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, James Stambaugh, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Which major investors are selling Intersect ENT stock?
XENT stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Royce & Associates LP, Bank of New York Mellon Corp, Bank of America Corp DE, Sivik Global Healthcare LLC, California Public Employees Retirement System, Russell Investments Group Ltd. and Mackay Shields LLC. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.
Which major investors are buying Intersect ENT stock?
XENT stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., BlackRock Inc., FMR LLC, First Trust Advisors LP, Cadian Capital Management LP, International Biotechnology Trust PLC, C WorldWide Group Holding A S and Bellevue Group AG. View Insider Buying and Selling for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $26.25.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $837.50 million and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
